Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation & Amortization (CF): 2016-2025

Historic Depreciation & Amortization (CF) for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $318,000.

  • Akebia Therapeutics' Depreciation & Amortization (CF) fell 12.40% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 15.65%. This contributed to the annual value of $1.5 million for FY2024, which is 7.76% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Depreciation & Amortization (CF) of $318,000 as of Q3 2025, which was up 0.63% from $316,000 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Depreciation & Amortization (CF) registered a high of $513,000 during Q1 2021, and its lowest value of $314,000 during Q1 2025.
  • Over the past 3 years, Akebia Therapeutics' median Depreciation & Amortization (CF) value was $364,000 (recorded in 2024), while the average stood at $363,182.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first increased by 0.76% in 2024, then decreased by 21.00% in 2025.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Depreciation & Amortization (CF) stood at $442,000 in 2021, then decreased by 7.69% to $408,000 in 2022, then declined by 3.43% to $394,000 in 2023, then declined by 14.97% to $335,000 in 2024, then dropped by 12.40% to $318,000 in 2025.
  • Its last three reported values are $318,000 in Q3 2025, $316,000 for Q2 2025, and $314,000 during Q1 2025.